BBI Solutions Adds More Antibodies to Product Range
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
BBI Solutions has continued to invest in its portfolio of antibodies and has announced the launch of 10 infectious disease markers, 3 inflammatory markers, 2 fertility markers and an additional cardiac marker. All the antibodies have been tested in either lateral flow or ELISA and are available for sampling today.
BBI Solutions (BBI) is in a rapid period of expansion and growth with recent announcements of a £14m investment into a global headquarters for the BBI Group and a recent acquisition of Maine Biotechnology Services. This further investment in to the expansion of BBI’s antibodies portfolio forms another part of the company’s growth plans as they continually aim to meet the growing demands of their customers.
BBI’s new infectious disease markers include H. pylori, Influenza A and B, E. coli O157, Campylobacter and Legionella pneumophila. BBI have also released antibodies for three inflammatory markers; Calprotectin, CRP and IL-6, two fertility markers; AMH and Estriol and Myoglobin antibodies as a cardiac marker.
James Steggles, BBI’s Antibodies Commercial Manager explained “we are pleased to be able to offer this range of high quality antibodies that test developers can use with confidence as part of their research and development assay programs. As they aim to improve diagnosis of key diseases and conditions.”
BBI’s mission is to deliver exceptional products and technologies that people rely on to enjoy a better quality of life. “We have selected these antibodies following requests from our customers. They also work towards achieving our mission and our growth plans”, continued James.
All of BBI’s new antibodies have either been tested in lateral flow or ELISA assays, many are already being used in commercial assays and there are a number of recommended matched pairs, which will save time and money in customer’s screening processes.
BBI Solutions (BBI) is in a rapid period of expansion and growth with recent announcements of a £14m investment into a global headquarters for the BBI Group and a recent acquisition of Maine Biotechnology Services. This further investment in to the expansion of BBI’s antibodies portfolio forms another part of the company’s growth plans as they continually aim to meet the growing demands of their customers.
BBI’s new infectious disease markers include H. pylori, Influenza A and B, E. coli O157, Campylobacter and Legionella pneumophila. BBI have also released antibodies for three inflammatory markers; Calprotectin, CRP and IL-6, two fertility markers; AMH and Estriol and Myoglobin antibodies as a cardiac marker.
James Steggles, BBI’s Antibodies Commercial Manager explained “we are pleased to be able to offer this range of high quality antibodies that test developers can use with confidence as part of their research and development assay programs. As they aim to improve diagnosis of key diseases and conditions.”
BBI’s mission is to deliver exceptional products and technologies that people rely on to enjoy a better quality of life. “We have selected these antibodies following requests from our customers. They also work towards achieving our mission and our growth plans”, continued James.
All of BBI’s new antibodies have either been tested in lateral flow or ELISA assays, many are already being used in commercial assays and there are a number of recommended matched pairs, which will save time and money in customer’s screening processes.
